Growth Investment

Steadily executing growth investments based on relationships with customers, such as primary batteries for medical devices

・Sequentially execute mass production investments in 3 focus areas based on specifications that have been finalized through alignment and relationships with customers

・Going forward, continue to allocate funds for capital investments and M&A for business growth without slowing the pace

3 focus areas Mobility Battery ICT/AI Semiconducter DMS Human medical

Shareholder Returns

In addition to dividends, executed share buybacks to improve capital efficiency

・The total payout ratio in the first year is forecasted to exceed 180％, with dividend of 2.2 billion yen and share buyback of 5 billion yen

・Going forward, aim for total payout ratio of over 100％ during the MEX26 period through continuous shareholder return measures, while maximizing capital efficiency by controlling equity

3 years cumulative Total Payout Ratio over 100%

by Updates on Mid-Term Plan MEX26